Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.31 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4255753 | 0.84 | CNR2 (0.34) | HSD11B1ALDH1A1SMN1; SMN2NPSR1CNR2 | |
| SCHEMBL75717 | 0.83 | HSD11B1 (0.34) | HSD11B1ALDH1A1SMN1; SMN2NPSR1CNR2 | |
| SCHEMBL4253450 | 0.83 | HSD11B1 (0.34) | HSD11B1ALDH1A1SMN1; SMN2NPSR1CNR2 | |
| SCHEMBL1574084 | 0.83 | HSD11B1 (0.35) | HSD11B1SMN1; SMN2CNR2 | |
| SCHEMBL4251570 | 0.83 | HSD11B1 (0.35) | HSD11B1SMN1; SMN2CNR2 | |
| SCHEMBL4264917 | 0.81 | CNR2 (0.31) | HSD11B1ALDH1A1CNR2 | |
| SCHEMBL76306 | 0.81 | CNR2 (0.31) | HSD11B1ALDH1A1CNR2 | |
| SCHEMBL4257970 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL75434 | 0.81 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL4253053 | 0.80 | CNR2 (0.40) | HSD11B1ALDH1A1NPSR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| US-8129423-B2 | 1-Adamantan-2-yl-3-benzyl-1,3-dihydro-imidazol-2-one; 11beta-hydroxysteroid dehydrogenases (11beta-HSD) inhibitor; antidiabetic, hypotensive, hypoglycemic agent; resist hyperglycemia provoked by obesity or stress; | HOFFMAN-LA ROCHE INC. (US) | 2012-03-06 | — | — | US | disclosed |
| EP-2308851-A1 | Imidazolone and imidazolidinone derivatives as 11B-HSD1 inhibitors for the treatment of diabetes | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |